TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03466112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance training
Description: endurance training with stationary bicycles
Study: NCT00413660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT03896477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
Study: NCT01179308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General-epidural anesthesia
Description: General anesthesia combined with epidural anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced general anesthesia and postoperative opioids
Description: General anesthesia alone
Study: NCT04716608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy program
Description: physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care treatment
Description: stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
Study: NCT01138085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: AKT Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: AKT Inhibitor
Study: NCT04169178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
Study: NCT05113654

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
Study: NCT03632707

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic Resonance Imaging of the knee
Description: After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Knee Arthroscopy
Description: Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
Study: NCT01166217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state.
Study: NCT02342769

Intervention type: DRUG
Intervention: Dolutegravir/Abacavir/Lamivudin
Description: Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
Study: NCT03466112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance and tone program
Description: flexibility, core strength, balance, relaxation
Study: NCT01616212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy /Adol and PW for parents
Description: Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for adolescents
Description: Motivational Enhancement Therapy for adolescents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Education for adolescents, Parenting Wisely for parents
Description: Drug Education for adolescents, Parenting Wisely for parents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Education for adolescents
Description: Drug Education for adolescents
Study: NCT03399942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain Stimulation of cingulum anterior
Description: The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain Stimulation of cingulum anterior
Description: The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
Study: NCT01792297

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Study: NCT00375427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Study: NCT03782623

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of eicosanoid profile prior to and after PRBC transfusion
Description: Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of eicosanoid profile prior to and after PRBC transfusion
Description: Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of eicosanoid profile prior to and after PRBC transfusion
Description: Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
Study: NCT04011735

Intervention type: DRUG
Intervention: Respimat
Description: Soft Mist Inhaler product

Intervention type: DRUG
Intervention: Respimat
Description: Soft Mist Inhaler product
Study: NCT02633046

Intervention type: DRUG
Group type: OTHER
Intervention: Acthar Gel
Description: Acthar Gel 80 U/mL solution for subcutaneous injection
Study: NCT03073343

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine (trimethyglycine)
Description: Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine (trimethyglycine)
Description: Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
Study: NCT00602511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity
Study: NCT01100645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sominex
Description: Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient
Study: NCT04277832

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionary
Description: All patients will answer two different questionary (TUPAST, TOPAS 2)
Study: NCT02142504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Placebo-matching norovirus bivalent VLP vaccine
Study: NCT03904784

Intervention type: BEHAVIORAL
Intervention: school withdrawal teenagers
Description: The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
Study: NCT02923310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Rich Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Rich Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucocyte - Platelets Rich Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucocyte - Platelets Rich Plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hialuronic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hialuronic Acid
Study: NCT00617591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: 40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days on 1-4
Study: NCT02854007

Intervention type: DEVICE
Intervention: Coronary angioplasty with implant of bioresorbable device
Description: Percutaneous coronary intervention
Study: NCT00605072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine, long acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine, long acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, long-acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, long-acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
Study: NCT03372564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Capsule Repair
Description: In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
Study: NCT01875705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: Escalating doses of GDC-0994 until maximum tolerated dose is reached
Study: NCT01309932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study: NCT01227226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears
Description: Instill one drop of artificial tears

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears
Description: Instill one drop of artificial tears

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears
Description: Instill one drop of artificial tears

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears
Description: Instill one drop of artificial tears
Study: NCT04519034

Intervention type: OTHER
Intervention: no intervention
Description: There will be no intervention

Intervention type: OTHER
Intervention: no intervention
Description: There will be no intervention
Study: NCT03947671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapr Rounds Hyper/Hypothermia Wraps
Description: Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapr Rounds Hyper/Hypothermia Wraps
Description: Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be administered as it would be per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be administered as it would be per standard of care
Study: NCT01875705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
Study: NCT03275428

Intervention type: DEVICE
Intervention: transnasal humidified rapid-insufflation ventilator exchange
Description: high flow nasal cannula with humidified oxygen
Study: NCT00425100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
Study: NCT02361619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: perpetrator
Study: NCT01309932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study: NCT01240213

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2000 IU per day of Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo per day
Study: NCT02688426

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Level Laser Therapy (Sham LLLT)
Description: perform with the machine off

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Low-Level Laser Therapy (Sham LLLT)
Description: perform with the machine off

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 6J Low-Level Laser Therapy (6J LLLT)
Description: irradiation will be perform with 6J

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J Low-Level Laser Therapy (6J LLLT)
Description: irradiation will be perform with 6J
Study: NCT03832036

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paraspinal Mapping and Quantitative Sensory Pain Test
Description: Participants will be tested at baseline.
Study: NCT02163486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group U (UNIQUE)
Description: Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-GEL
Description: Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc
Study: NCT02618408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (18 mg)
Description: Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (36 mg)
Description: Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study: NCT00218166

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GABA Agonists
Description: GABA drugs administered acutely by mouth
Study: NCT00662948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 every 8 weeks during 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab tiuxetan
Description: One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
Study: NCT00160641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study.
Study: NCT03715075

Intervention type: PROCEDURE
Intervention: Caesarean Section
Description: Caesarean Section
Study: NCT03915730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy
Description: Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy
Description: Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
Study: NCT03812705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiome transplantation
Description: 1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation.